Equol as a potent radiosensitizer in estrogen receptor-positive and -negative human breast cancer cell lines

Taghizadeh, Bita; Ghavami, Laleh; Nikoofar, Alireza; Goliaei, Bahram

doi:10.1007/s12282-013-0492-0

Cited by 22 publications

(12 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…For example, in human breast cancer cells and cervical cancer cells, equol elicited the apoptosis pathway through cytochrome c‐mediated caspases cascade (Choi, Ahn, & Bae, ; Kim, Shin, Park, & Kim, ). Recently, it was discovered that equol could be taken as an emerging radio sensitizer due to its excellent capability of enhancing the radiation‐induced apoptosis in breast cancer cells T47D as well as MDA‐MB‐231 (Taghizadeh, Ghavami, Nikoofar, & Goliaei, ). Evidence suggested that equol has the potential to lower the prostate‐specific antigen levels in human prostate cancer cells under 5α‐dihydrotestosterone (5α‐DHT) stimulation and to improve prostate health by reducing serum 5α‐DHT levels and androgen hormone action in Long–Evans rats (Lund et al, ).…”

Section: The Bioactivities and Clinical Applications Of Equolmentioning

confidence: 99%

See 1 more Smart Citation

Advances in exploring equol production and application

2019

J Food Process Preserv

View full text Add to dashboard Cite

The soybean isoflavone daidzein has been extensively studied. Equol represents the main active metabolite of daidzein in vivo. Due to its broadly biological activities, the preparation and characterization of equol have attracted a great deal of interest. In this review, the focus of attention is placed on the approaches to equol production, including the total synthesis of equol, equol from natural bacteria fermentation and synthetic biology for equol production. It is expected that the industrial production of equol with high yield could be realized in an economic way in the future. In addition, pharmacological activities and clinical applications of equol are also discussed to gain a systematically understanding as to the prospect of development for equol. Practical applications Equol is the main active metabolite of daidzein in vivo and considered to be the most active metabolite of the soybean isoflavones. It has broadly biological activities, including antitumor, antioxidative properties, cardiovascular protection, and relieve menopausal symptoms. However, only 25%–30% of young people can excrete equol in vivo when supplied with soy foods. So, it is necessary to develop efficient methods for equol preparation. Meanwhile, more systematic researches for the pharmacological activity of equol are also required. As mentioned above, this manuscript entitled “Advances in exploring Equol production and application,” hoping that this review should draw widespread attention.

show abstract

Section: The Bioactivities and Clinical Applications Of Equolmentioning

confidence: 99%

“…Recently, it was discovered that equol could be taken as an emerging radio sensitizer due to its excellent capability of enhancing the radiation-induced apoptosis in breast cancer cells T47D as well as MDA-MB-231 (Taghizadeh, Ghavami, Nikoofar, & Goliaei, 2015).…”

Section: Antitumormentioning

confidence: 99%

Advances in exploring equol production and application

2019

J Food Process Preserv

View full text Add to dashboard Cite

show abstract

“…Interests in soy isoflavones have been fueled by studies attributing the consumption of soy foods to an increase in metastasis. However, equol, the major metabolite of the soybean isoflavone daidzein, was considered to be a radiosensitizing agent and its effects may be due to increasing DNA damage in two human breast cancer cell lines (T47D and MDA‐MB‐231) . Clinical studies have established that epigallocatechin‐3‐gallate (EGCG), the most abundant catechin in green tea leaves, potentiated efficacy of radiotherapy in breast cancer patients .…”

Section: Sensitization Mechanisms Of Natural Phytochemicals In Breastmentioning

confidence: 99%

Prevention of Breast Cancer by Natural Phytochemicals: Focusing on Molecular Targets and Combinational Strategy

Chiou

et al. 2018

Molecular Nutrition Food Res

View full text Add to dashboard Cite

Starting from the 21st century, breast cancer can be classified as the most common invasive malignancy in women. Among the preventive or therapeutic strategies of breast cancer, combination therapy is the most promising approach. This mode of treatment of breast cancer concurrently maximizes efficacy, overcomes multidrug resistance, and minimizes harmful side effects caused by radiotherapy and chemotherapy alone. The risk of cancer can be reduced by supplementing diets with naturally occurring products known as phytochemicals. These phytochemicals have well-defined roles in the management of every stage of breast carcinogenesis. In this review, the collective data of dietary phytochemicals used to sensitize breast cancer cells to therapeutic approaches are reported and their specific molecular targets through synergistic, additive, and potentiation effects are highlighted. The concept of combining natural agents with medicines to augment therapeutic responses creates an optimal modality, which may facilitate clinical applications of combination regimens in the future.

show abstract

“…Radiation response modifier is designed for enhancing apoptosis of cancer cells while having much less effect on normal tissues. To develop modifier, in vitro studies are first step for novel radio-sensitizing agents driving cell death based on biological behavior of cancer cells (Alcorn et al ., 2013; Cho et al ., 2015; Taghizadeh et al ., 2015). In this study, JC3 was evaluated for whether it could be applied to modify radio-resistant breast cancer cells.…”

Section: Introductionmentioning

confidence: 99%

A Benzylideneacetophenone Derivative Induces Apoptosis of Radiation-Resistant Human Breast Cancer Cells via Oxidative Stress

Park

Piao

Kang

et al. 2017

Biomolecules & Therapeutics

View full text Add to dashboard Cite

Benzylideneacetophenone derivative (1E)-1-(4-hydroxy-3-methoxyphenyl) hept-1-en-3-one (JC3) elicited cytotoxic effects on MDA-MB 231 human breast cancer cells-radiation resistant cells (MDA-MB 231-RR), in a dose-dependent manner, with an IC50 value of 6 μM JC3. JC3-mediated apoptosis was confirmed by increase in sub-G1 cell population. JC3 disrupted the mitochondrial membrane potential, and reduced expression of anti-apoptotic B cell lymphoma-2 protein, whereas it increased expression of pro-apoptotic Bcl-2-associated X protein, leading to the cleavage of caspase-9, caspase-3 and poly (ADP-ribose) polymerase. In addition, JC3 activated mitogen-activated protein kinases, and specific inhibitors of these kinases abrogated the JC3-induced increase in apoptotic bodies. JC3 increased the level of intracellular reactive oxygen species and enhanced oxidative macromolecular damage via lipid peroxidation, protein carbonylation, and DNA strand breakage. Considering these findings, JC3 is an effective therapy against radiation-resistant human breast cancer cells.

show abstract

Equol as a potent radiosensitizer in estrogen receptor-positive and -negative human breast cancer cell lines

Abstract: These results suggest for the first time that equol can be considered as a radiosensitizing agent and its effects may be due to increasing cell death following irradiation, increasing the remaining radiation-induced DNA damage and thus reducing the surviving fraction of irradiated cells.

Cited by 22 publications

References 47 publications

Advances in exploring equol production and application

Advances in exploring equol production and application

Prevention of Breast Cancer by Natural Phytochemicals: Focusing on Molecular Targets and Combinational Strategy

A Benzylideneacetophenone Derivative Induces Apoptosis of Radiation-Resistant Human Breast Cancer Cells via Oxidative Stress

Contact Info

Product

Resources

About